Published in Obesity and Diabetes Week, February 7th, 2005
Totaling more than $30 billion, the metabolic syndrome drug market, which includes type 2 diabetes, obesity, dyslipidemia, and hypertension, is an example of such a co-morbid patient population that offers huge commercial opportunity.
To assist organizations in identifying the prevalent population of metabolic syndrome sufferers in the United States,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week